Table I. Double-blind, randomized clinical studies included in the meta-analysis.

Ref.	Year	No. patients	Type of study	Dose	Period of treatment	Therapeutic indication	Clinical endpoints
6	1979	14	Double-blind	8 mg x 4/day	20 days	Vertiginous syndromes	Therapeutic efficacy
7	1981	32	Double-blind;	16 mg +	20 weeks	Vertiginous syndromes	Therapeutic efficacy, vestibular examination, audiometry, tolerability
			Cross-over	8 mg +
				8 mg/day
8	1984	24	Double-blind;	12 mg x 3/day	6 weeks	Vertiginous syndromes	Therapeutic efficacy, audiometry, vestibular examination, tolerability
			Cross-over
9	1988	81	Double-blind	16 mg x 3/day	12 weeks	Vertiginous syndromes	Therapeutic efficacy,
							tolerability
10	1989	82	Double-blind;	16 mg x 3/day	5 weeks	Benign paroxysmal vertigo	Therapeutic efficacy, tolerability
			Cross-over
11	1985	73	Double-blind	16 mg x 3/day	16 weeks	Benign paroxysmal vertigo	Therapeutic efficacy
12	2003	63	Double-blind	16 mg x 2	3 months	Vertiginous syndromes	Therapeutic efficacy, tolerability